American Journal of Marine Science
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Marine Science. 2014, 2(1), 1-8
DOI: 10.12691/marine-2-1-1
Open AccessReview Article

The Potential Applications of Marine Bioactives Against Diabetes and Obesity

Hang Wang1, Zhi-ming Fu1 and Chun-chao Han1,

1School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, P. R.China

Pub. Date: December 26, 2013

Cite this paper:
Hang Wang, Zhi-ming Fu and Chun-chao Han. The Potential Applications of Marine Bioactives Against Diabetes and Obesity. American Journal of Marine Science. 2014; 2(1):1-8. doi: 10.12691/marine-2-1-1


Diseases caused by metabolic dysfunction such as diabetes and obesity have serious effect on human’s health. Hence, it’s important for human to find effective functional food or drugs against metabolic dysfunction. The marine environment represents a relatively untapped source that can be applied to various aspects. Meanwhile, numerous marine-based compounds have been identified as having diverse biological activities, with some reported to interfere with the pathogenesis of diseases. On the basis of their bioactive properties, this review focuses on the potential use of marine-derived compounds to against metabolic dysfunction, including diabetes and obesity.

marine bioactives diabetes obesity metabolic dysfunction

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 5


[1]  Pontiroli AE and Camisasca R, “Additive effect of overweight and type 2 diabetes in the appearance of coronary heart disease but not of stroke: a cross-sectional study,” Acta Diabetol, 39(2):83-90, 2002.
[2]  Grundy SM, Bryan Brewer JH, Cleeman JI, Sidney J, Smith C and Lenfant C, “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition,” Circulation, 109: 433-438, 2004.
[3]  Sinéad Lordan, R. Paul Ross, and Catherine Stanton, “Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases,” Marine Drugs, 9:1056-1100, 2011.
[4]  Dembitsky, V.M., and Maoka, “T. Allenic and cumulenic lipids,” Progress in Lipid Research, 46:328-375, 2007.
[5]  Nomura T., Kikuchi M., Kubodera A., and Kawakami, Y., “Proton-donative antioxidant activity of fucoxanthin with 1,1-diphenyl-2-picrylhydrazyl (DPPH),” Biochemistry and Molecular Biology International, 42:361-370, 1997.
[6]  Hayato Maeda, Masashi Hosokawa, Tokutake Sashima, and Kazuo Miyashita, “Dietary Combination of Fucoxanthin and Fish Oil Attenuates the Weight Gain of White Adipose Tissue and Decreases Blood Glucose in Obese/Diabetic KK-Ay Mice,” Journal of Agricultural and Food Chemistry, 55:7701-7706, 2007.
[7]  Nicolantonio D’Orazio, Eugenio Gemello, Maria Alessandra Gammone Massimo de Girolamo, Cristiana Ficoneri, and Graziano Riccioni, “Fucoxantin: A Treasure from the Sea,” Marine Drugs, 10: 604-616, 2012.
[8]  Juan Peng, Jian-Ping Yuan, Chou-Fei Wu, and Jiang-Hai Wang, “Fucoxanthin, a Marine Carotenoid Present in Brown Seaweeds and Diatoms: Metabolism and Bioactivities Relevant to Human Health,” Marine Drugs, 9:1806-1828, 2011.
[9]  Tsukui T., Konno K., Hosokawa M., Maeda H., Sashima T., Miyashita K, “Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in the liver of KKAy obese/diabetic mice,” Journal of Agricultural and Food Chemistry, 55:5025-5029, 2007.
[10]  Perugini M., D’orazio N., Manera M., et al., “Total mercury in fish from the Central Adriatic Sea in relation to levels found in the hair of fishermen,” Journal of Veterinary Pharmacology and Therapeutics, 29:176-177, 2006.
[11]  Zaccaroni A., Perugini M., D’orazio N., et al., “Investigation of total arsenic in fish from the Central Adriatic Sea (Italy) in relation to levels found in fishermen’s Hair,” Journal of Veterinary Pharmacology and Therapeutics, 29:178-179, 2006.
[12]  Woo M.N., Jeon S.M., Shin Y.C., Lee M.K., Kang M.A., and Choi M.S., “Anti obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice,” Molecular Nutrition & Food Research, 53:1603-1611, 2009.
[13]  Myoung-Nam Woo, Seon-Min Jeon, Young Chul Shin, Mi-Kyung Lee, Mi Ae Kang, and Myung-Sook Choi, “Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice,” Molecular Nutrition & Food Research, 53:1603-1611, 2009.
[14]  Seon-Min Jeon, Hye-Jin Kim, Myoung-Nam Woo1, et al., “Fucoxanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J mice,” Journal of Biotechnology, 5: 961-969, 2010.
[15]  Xiaojie Hu, Yanmei Li, Chunhua Li, et al., “Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats,” Archives of Biochemistry and Biophysics, 519: 59-65, 2012.
[16]  Ghazi Hussein, Ushio Sankawa, Hirozo Goto, Kinzo Matsumoto, and Hiroshi Watanabe, “Astaxanthin, a Carotenoid with Potential in Human Health and Nutrition,” Journal of Natural Products, 69: 443-449, 2006.
[17]  Jian-Ping Yuan, Juan Peng, Kai Yin, and Jiang-Hai Wang, “Potential health-promoting effects of astaxanthin: A high-value carotenoid mostly from microalgae,” Molecular Nutrition & Food Research, 55: 150-165, 2011.
[18]  Elumalai Arunkumar, Saravanan Bhuvaneswari, and Carani Venkatraman Anuradha, “An intervention study in obese mice with astaxanthin, a marine carotenoid-effects on insulin signaling and pro-inflammatory cytokines,” Food Functional, 3: 120-126, 2012.
[19]  Uchiyama K., Naito Y., Hasegawa G., et al., “Astaxanthin protects b-cells against glucose toxicity in diabetic db/db mice,” Redox Report, 7: 290-293, 2002.
[20]  Bhuvaneswari S., Arunkumar E., Viswanathan P., and Anuradha C. V., “Astaxanthin restricts weight gain, promotes insulin sensitivity and curtails fatty liver disease in mice fed an obesity-promoting diet,” Process Biochemistry, 45: 1406-1414, 2010.
[21]  Hussein G., Nakagawa T., Goto H., et al., “Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp,” Life Sciences, 80: 522-529, 2007.
[22]  Ikeuchi M, Koyama T, Takahashi J, and Yazawa K., “Effects of astaxanthin in obese mice fed a high-fat diet,” Biosci Biotechnol Biochemistry, 71(4): 893-9, 2007.
[23]  Hye Duck Choi, Ji Hae Kim, Min Jung Chang, Yeo Kyu‐Youn, and Wan Gyoon Shin, “Effects of Astaxanthin on Oxidative Stress in Overweight and Obese Adults,” Phytother Research, 25(12): 1813-8, 2011.
[24]  Liang J, Pei XR, Wang N, et al., “Marine collagen peptides prepared from chum salmon (Oncorhynchusketa) skin extend the life span and inhibit spontaneous tumor incidence in Sprague–Dawley Rats,” Journal of Medicinal Food, 13:757-770, 2010.
[25]  Cui-Feng Zhu, Guan-Zhi Li, Hong-Bin Peng, Fan Zhang, Yun Chen, and Yong Li, “Effect of Marine Collagen Peptides on Markers of Metabolic Nuclear Receptors in Type 2 Diabetic Patients with/without Hypertension,” Biomedical and Environmental Sciences, 23: 113-120, 2010.
[26]  Pei X, Yang R, Zhang Z, et al., “Marine collagen peptide isolated from chum salmon (Oncorhynchus keta) skin facilitates learning and memory in aged C57BL/6J mice,” Food Chemistry, 118: 333-340, 2010.
[27]  Zhang F, Wang Z, and Xu S, “Macroporous resin purification of grass carp fish (Ctenopharyngodon idella) scale peptides with in vitro angiotensin-I converting enzyme (ACE) inhibitory ability,” Food Chemistry, 117: 387-392, 2009.
[28]  Tanaka M, Koyama Y, and Nomura Y, “Effects of collagen peptide ingestion on UV-B-induced skin damage,” Biosci Biotechnol Biochemistry, 73: 930-932, 2009.
[29]  Zolotarev Iu A, Badmaeva KE, Bakaeva ZV, et al., “Short peptide fragments with antiulcer activity from a collagen hydrolysate,” Bioorganicheskaya Khimiya, 32: 192-197, 2006.
[30]  Saito M, Kiyose C, Higuchi T, et al. “Effect of collagen hydrolysates from salmon and trout skins on the lipid profile in rats,” Journal of Agricultural and Food Chemistry, 57: 10477-10482, 2009.
[31]  Cui-Feng Zhu, Guan-Zhi Li, Hong-Bin Peng, Fan Zhang, Yun Chen, and Yong Li, “Treatment with marine collagen peptides modulates glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus,” Applied Physiology, Nutrition and Metabolism, 35: 797-804, 2010.
[32]  Cui-Feng Zhu, Guan-Zhi Li, Hong-Bin Peng, Fan Zhang, Yun Chen, and Yong Li, “Therapeutic Effects of Marine Collagen Peptides on Chinese Patients With Type 2 Diabetes Mellitus and Primary Hypertension,” The American Journal of the Medical Sciences, 340(5): 360-366, 2010.
[33]  Lee S.H., Min K.H., Han J.S., et al., “Effect of brown algae, Ecklonia cava on glucose and lipid metabolism in C57bl/KsJ-db/db mice, a model of type 2 diabetes mellitus,” Food and Chemical Toxicology, 50: 575-582, 2012.
[34]  Min-Cheol Kang, W.A.J.P. Wijesinghe, Seung-Hong Lee, et al., “Dieckol isolated from brown seaweed Ecklonia cava attenuates type II diabetes in db/db mouse model,” Food and Chemical Toxicology, 53: 294-298, 2013.
[35]  Seung-Hong Lee, Lee SH, Park MH, et al. “Dieckol isolated from Ecklonia cava protects against high-glucose induced damage to rat insulinoma cells by reducing oxidative stress and apoptosis,” Biosci Biotechnol Biochemistry, 76(8): 1445-51, 2012.
[36]  Seung-Hong Lee, Ji-Sook Han, Soo-Jin Heo, Ji-Young Hwang, and You-Jin Jeon, “Protective effects of dieckol isolated from Ecklonia cava against high glucose-induced oxidative stress in human umbilical vein endothelial cells,” Toxicology in Vitro, 24: 375-381, 2010.
[37]  Isuru Wijesekara, Na Young Yoon, and Se-Kwon Kim, “Phlorotannins from Ecklonia cava (Phaeophyceae): Biological activities and potential health benefits,” International Union of Biochemistry and Molecular Biology, 36( 6): 408-414, 2010.
[38]  Yuxi Wei, Chuanjin Xu, Qi Liu, et al., “Effect of phlorotannins from Sargassum thunbergii on blood lipids regulation in mice with high-fat diet,” Natural Product Research, 26(22): 2117-2120, 2012.
[39]  Na Young Yoon, Hyeung Rak Kim, Hae Young Chung, and Jae Sue Choi, “Anti-hyperlipidemic Effect of an Edible Brown Algae, Ecklonia stolonifera, and its Constituents on Poloxamer 407-Induced Hyperlipidemic and Cholesterol-fed Rats,” Archives of Pharmacal Research, 31(12): 1564-1571, 2008.
[40]  Ruxandra Bunea, Khassan El Farrah, Luisa Deutsch, “Evaluation of the Effects of Neptune Krill Oil on the Clinical Course of Hyperlipidemia,” Alternative Medicine Review, 9(4): 420-428, 2004.
[41]  Ferramosca A, Conte A, Burri L, et al., “A krill oil supplemented diet suppresses hepatic steatosis in high-fat fed rats,” PLoS One, 7: e38797, 2012.
[42]  Tandy S, Chung RW, Wat E, et al, “Dietary krill oil supplementation reduces hepatic steatosis, glycemia, and hypercholesterolemia in high-fat-fed mice,” J Agric Food Chemistry. 57: 9339-9345, 2009.
[43]  Deutsch L, “Evaluation of the effect of Neptune krill oil on chronic inflammation and arthritic symptoms,” Journal of the American College of Nutrition, 26: 39-48, 2007.
[44]  Grimstad T, Bjørndal B, Cacabelos D, et al., “Dietary supplementation of krill oil attenuates inflammation and oxidative stress in experimental ulcerative colitis in rats,” Scandinavian Journal of Gastroenterology, 47: 49-58, 2012.
[45]  Gigliotti JC, Davenport MP, Beamer SK, Tou JC and Jaczynski J, “Extraction and characterisation of lipids from Antarctic krill (Euphausia superba),” Food Chemistry, 125: 1028-1036, 2011.
[46]  Zhu JJ, Shi JH, Qian WB, Cai ZZ and Li D, “Effects of krill oil on serum lipids of hyperlipidemic rats and human SW480 cells,” Lipids in Health and Disease, 7: 30, 2008.
[47]  Marzo VD, Griinari M, Carta G, et al., “Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats,” Journal of Dairy Science, 20: 231-235, 2010.
[48]  Piscitelli F, CartaG, Bisogno T, et al., “Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice,” Nutrition Metabolic, 8: 51, 2011.
[49]  Fosshaug LE, Berge RK, Beitnes JO, et al., “Krill oil attenuates left ventricular dilatation after myocardial infarction in rats,” Lipids in Health and Disease, 10: 245 2011.
[50]  Sally Tandy, Rosanna W. S. Chung, Elaine Wat, et al., “ietary Krill Oil Supplementation Reduces Hepatic Steatosis, Glycemia, and Hypercholesterolemia in High-Fat-Fed Mice,” Journal of Agricultural and Food Chemistry, 57: 9339-9345, 2009.
[51]  Jia-Jin Zhu, Jia-Hui Shi, Wen-Bin Qian, Zhen-Zhen Cai, and Duo Li, “Effects of Krill Oil on serum lipids of hyperlipidemic rats and human SW480 cells,” Lipids in Health and Disease, 7: 30, 2008.
[52]  Dong-Mei Li, Da-Yong Zhou, Bei-Wei Zhu, et al., “Effects of krill oil intake on plasma cholesterol and glucose levels in rats fed a high-cholesterol diet,” Journal of the Science of Food and Agriculture, 2013.
[53]  Ruxandra Bunea, Khassan El Farrah, Luisa Deutsch, “Evaluation of the Effects of Neptune Krill Oil on the Clinical Course of Hyperlipidemia,” Alternative Medicine Review : A Journal of Clinical Therapeutic, 9(4): 420-8, 2004.
[54]  Kevin C. Maki, Mathew S. Reeves, Mildred Farmer, et al. “Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women,” Nutrition Research, 29(9): 609-15, 2009.
[55]  Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, and Di Marzo V, “Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets,” Molecular and Cellular Endocrinology, 286: S66-78, 2008.
[56]  Sebastiano Banni, Gianfranca Carta, Elisabetta Murru, et al. “Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects,” Nutrition & Metabolism, 8(1): 7, 2011.
[57]  Beress A, Wassermann O, Tahhan S, Bruhn T, Beress L, Kraiselburd EN, et al. A new procedure for the isolation of anti-HIV compounds (polysaccharides and polyphenols) from the marine algaFucus vesiculosus. Journal of Natural Products, 56:478-88, 1993.
[58]  Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H. Over sulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochemical Pharmacology, 65:173-9, 2003.
[59]  Kui-Jin Kim, Kye-Yoon Yoon, Boo-Yong Lee. Fucoidan regulate blood glucose homeostasis in C57BL/KSJ m+/+db and C57BL/KSJ db/db mice. Fitoterapia, 83: 1105-1109, 2012.
[60]  Yong-Tae Jeong, Yong Deuk Kim, Young-Mi Jung, et al. Low Molecular Weight Fucoidan Improves Endoplasmic Reticulum Stress-Reduced Insulin Sensitivity through AMP Activated Protein Kinase Activation in L6 Myotubes and Restores Lipid Homeostasis in a Mouse Model of Type 2 Diabetes. Molecular Pharmacology, 84:147-157, 2013.
[61]  Kim KJ, Lee OH, Lee BY. Fucoidan, a sulfated polysaccharide, inhibits adipogenesis through the mitogen-activated protein kinase pathway in 3T3-L1 preadipocytes. Life Sciences, 86:791-7, 2010.
[62]  Lutay N, Nilsson I, Wadstrom T, Ljungh A. Effect of heparin, fucoidan and other polysaccharides on adhesion of enterohepatic helicobacter species to murine macrophages. Applied Biochemistry and Biotechnology, 164:1-9, 2011.
[63]  Kui-Jin Kima and Boo-Yong Lee, “Fucoidan fromthe sporophyll of Undaria pinnatifida suppresses adipocyte differentiation by inhibition of inflammation-related cytokines in 3T3-L1 cells,” Nutrition Research, 32: 439-447, 2012.
[64]  Min-Kyoung Park, Uhee Jung and Changhyun Roh, “Fucoidan from Marine Brown Algae Inhibits Lipid Accumulation,” Marine Drugs, 9: 1359-1367, 2011.
[65]  Tao Sun, Qi Wang, Zhiguo Yu, et al. “Hyrtiosal, a PTP1B Inhibitor fromthe Marine Sponge Hyrtios erectus, Shows Extensive Cellular Effects on PI3K/AKT Activation, Glucose Transport, and TGFb/Smad2 Signaling,” Biophysical Chemistry, 8: 187-193, 2007.
[66]  S.N. Kim, H.Y. Choi, W. Lee, G.M. Park, W.S. Shin, and Y.K. Kim, “Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha/gamma activation in 3T3-L1 cells,” FEBS Letters, 582: 3465-3472, 2008.
[67]  Newman D. and Cragg G., “Marine natural products and related compounds in clinical and advanced preclinical trials,” Journal of Natural Products, 67: 1216-1238, 2004.